InhaTarget Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

InhaTarget Therapeutics is an early-stage, private biotech company pioneering targeted inhalation therapies for severe respiratory conditions, starting with lung cancer. As a 2019 ULB spin-off, it leverages strong expertise in formulation, delivery, and clinical development to repurpose or improve existing molecules via inhalation. The company is currently in the preclinical/early clinical stage, actively presenting at major conferences and seeking validation for its platform. Its mission is to change the treatment paradigm by enhancing efficacy, stability, and patient convenience through localized pulmonary delivery.

OncologyRespiratory Diseases

Technology Platform

Proprietary platform for developing targeted inhalation formulations designed to improve treatment modalities (route, frequency, mechanism, stability) for severe respiratory diseases.

Opportunities

The large and growing global market for lung cancer therapeutics presents a major opportunity for a localized treatment that can reduce systemic toxicity and improve patient outcomes.

The platform's potential application beyond oncology to other severe respiratory diseases like IPF and COPD significantly expands its addressable market.

Risk Factors

Key risks include the significant technical challenges of developing effective and tolerable inhaled formulations for complex diseases, an uncertain regulatory pathway for inhaled oncology drugs, and competition from better-funded entities in the growing pulmonary drug delivery space.

Competitive Landscape

The competitive landscape includes other biotechs developing inhaled therapies for cancer (e.g., WindMIL, Actuate Therapeutics) and large pharma companies with respiratory franchises exploring drug repurposing. InhaTarget's differentiation lies in its specific formulation expertise and its initial focus on repurposing for lung cancer via a targeted inhalation approach.

More companies in Drug Delivery & Formulation →More companies in Belgium →